Anti-Helicobacter pylori therapy in India:: Differences in eradication efficiency associated with particular alleles of vacuolating cytotoxin (vacA) gene

被引:9
作者
Chaudhuri, S
Chowdhury, A
Datta, S
Mukhopadhyay, AK
Chattopadhya, S
Saha, DR
Dhali, G
Santra, A
Nair, GB
Bhattacharya, S
Berg, DE
机构
[1] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO USA
[2] Postgrad Inst Med Educ & Res, Dept Gastroenterol, Kolkata, India
[3] Natl Inst Colera & Enter Dis, Kolkata, India
关键词
clarithromycin-based triple therapy; Helicobacter pylori eradication; vacA genotypes;
D O I
10.1046/j.1440-1746.2003.02944.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: The efficiency of Helicobacter pylori eradication varies geographically, as do many parameters that might affect therapeutic efficiency, including bacterial genotype. The aim of the present study was to determine the efficiency of H. pylori eradication using a 10-day proton pump inhibitor-based triple-therapy regimen (omeprazole, clarithromycin and amoxycillin) in an eastern Indian patient population, and to find out the relationship, if any, of the success or failure of the therapy to known features of bacterial genotype. Methods: Helicobacter pylori infections were analyzed in 66 duodenal ulcer patients by upper gastrointestinal endoscopy, rapid urease tests, histology and culture. The cytotoxin-associated gene (cagA) and vacuolating cytotoxin (vacA) gene status of cultured strains were studied by polymerase chain reaction. Treatment was given for 10 days and endoscopy was repeated at 4 and 12 weeks post therapy to monitor ulcer healing and H. pylori eradication. Results: Ulcer healing was observed in 60 patients (96.77%). Helicobacter pylori was eradicated in 41 (62.12% intention to treat, 66.13% per protocol) of the 66 duodenal ulcer patients, but not in the other 25. The bacteria from 47 patients were genotyped. The only significant disease-associated difference in patterns observed was that the vacA m1 allele was represented more disproportionately among patients with eradication failures (68%) than in those with successful eradication (39%) (P < 0.05) No significant association of vacAs1 (signal sequence allele) or cag pathogenicity island status with persistence was detected. Conclusions: This study highlights the public health need for cheaper, more cost-effective anti-H. pylori therapies for developing countries, and suggests that subtle features of bacterial genotype can influence therapeutic efficiency. The possibility that particular vacA mid region alleles affect persistence, perhaps through toxin action on particular gastric cell types, merits further study. (C) 2003 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:190 / 195
页数:6
相关论文
共 31 条
[1]   Recombination and clonal groupings within Helicobacter pylori from different geographical regions [J].
Achtman, M ;
Azuma, T ;
Berg, DE ;
Ito, Y ;
Morelli, G ;
Pan, ZJ ;
Suerbaum, S ;
Thompson, SA ;
van der Ende, A ;
van Doorn, LJ .
MOLECULAR MICROBIOLOGY, 1999, 32 (03) :459-470
[2]  
Ahuja V, 1998, ALIMENT PHARM THERAP, V12, P551, DOI 10.1046/j.1365-2036.1998.00338.x
[3]   DNA DIVERSITY AMONG CLINICAL ISOLATES OF HELICOBACTER-PYLORI DETECTED BY PCR-BASED RAPD FINGERPRINTING [J].
AKOPYANZ, N ;
BUKANOV, NO ;
WESTBLOM, TU ;
KRESOVICH, S ;
BERG, DE .
NUCLEIC ACIDS RESEARCH, 1992, 20 (19) :5137-5142
[4]  
Ausubel FM., 1993, Current Protocols in Molecular Biology
[5]   Helicobacter pylori eradication: Comparison of three treatment regimens in India [J].
Bhasin, DK ;
Sharma, BC ;
Sinha, SK ;
Ray, P ;
Vaiphei, K ;
Singh, K .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1999, 28 (04) :348-351
[6]  
Chowdhury Abhijit, 2002, Indian J Gastroenterol, V21, P23
[7]  
COVER TL, 2001, PRINCIPLES BACTERIAL, P509
[8]  
DebetsOssenkopp YJ, 1996, FEMS MICROBIOL LETT, V142, P37, DOI 10.1016/0378-1097(96)00239-X
[9]   Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy -: A meta-analytical approach [J].
Dore, MP ;
Leandro, G ;
Realdi, G ;
Sepulveda, AR ;
Graham, DY .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (01) :68-76
[10]  
Fallone CA, 1999, CLIN INVEST MED, V22, P185